{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:09:05Z","timestamp":1789196945135,"version":"build-2803163510"},"publisher-location":"Berlin, Heidelberg","reference-count":68,"publisher":"Springer Berlin Heidelberg","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/164_2026_827","type":"book-chapter","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:29:00Z","timestamp":1789194540000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Evidence of Cardioprotective Effects of SGLT2 Inhibitors"],"prefix":"10.1007","author":[{"given":"Muhammad Shariq","family":"Usman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambarish","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,13]]},"reference":[{"issue":"6","key":"827_CR1","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.121.058910","volume":"146","author":"C Adamson","year":"2022","unstructured":"Adamson C, Docherty KF, Heerspink HJ, De Boer RA, Damman K, Inzucchi SE et al (2022) Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation 146(6):438\u2013449","journal-title":"Circulation"},{"issue":"21","key":"827_CR2","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1001\/jama.2024.6892","volume":"331","author":"R Aggarwal","year":"2024","unstructured":"Aggarwal R, Ostrominski JW, Vaduganathan M (2024) Prevalence of cardiovascular-Kidney-metabolic syndrome stages in US adults, 2011\u20132020. JAMA 331(21):1858\u20131860","journal-title":"JAMA"},{"issue":"16","key":"827_CR3","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451\u20131461","journal-title":"N Engl J Med"},{"key":"827_CR4","doi-asserted-by":"publisher","unstructured":"Bajaj M, McCoy RG, Balapattabi K, Bannuru RR, Bellini NJ, Bennett AK et al (2026a) 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142026. Diabetes Care. https:\/\/doi.org\/10.2337\/dc26-S009","DOI":"10.2337\/dc26-S009"},{"key":"827_CR5","doi-asserted-by":"publisher","unstructured":"Bajaj M, McCoy RG, Balapattabi K, Bannuru RR, Bellini NJ, Bennett AK et al (2026b) 10. Cardiovascular disease and risk management: standards of care in diabetes\u20142026. Diabetes Care. https:\/\/doi.org\/10.2337\/dc26-S010","DOI":"10.2337\/dc26-S010"},{"issue":"5","key":"827_CR6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamacardio.2020.7585","volume":"6","author":"DD Berg","year":"2021","unstructured":"Berg DD, Jhund PS, Docherty KF, Murphy SA, Verma S, Inzucchi SE et al (2021) Time to clinical benefit of Dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. JAMA Cardiol 6(5):499\u2013507","journal-title":"JAMA Cardiol"},{"issue":"2","key":"827_CR7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK et al (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384(2):117\u2013128","journal-title":"N Engl J Med"},{"issue":"13","key":"827_CR8","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/eurheartj\/ehaa1007","volume":"42","author":"J Butler","year":"2021","unstructured":"Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ et al (2021) Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J 42(13):1203\u20131212","journal-title":"Eur Heart J"},{"issue":"5","key":"827_CR9","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","volume":"43","author":"J Butler","year":"2022","unstructured":"Butler J, Packer M, Filippatos G, Ferreira JP, Zeller C, Schnee J et al (2022a) Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J 43(5):416\u2013424","journal-title":"Eur Heart J"},{"issue":"3","key":"827_CR10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.121.057812","volume":"145","author":"J Butler","year":"2022","unstructured":"Butler J, Filippatos G, Jamal Siddiqi T, Brueckmann M, B\u00f6hm M, Chopra VK et al (2022b) Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-preserved trial. Circulation 145(3):184\u2013193","journal-title":"Circulation"},{"issue":"16","key":"827_CR11","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","volume":"390","author":"J Butler","year":"2024","unstructured":"Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J et al (2024) Empagliflozin after acute myocardial infarction. N Engl J Med 390(16):1455\u20131466","journal-title":"N Engl J Med"},{"issue":"15","key":"827_CR12","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383(15):1425\u20131435","journal-title":"N Engl J Med"},{"issue":"6","key":"827_CR13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.16290","volume":"6","author":"UR Essien","year":"2023","unstructured":"Essien UR, Singh B, Swabe G, Johnson AE, Eberly LA, Wadhera RK et al (2023) Association of Prescription co-payment with Adherence to glucagon-like Peptide-1 receptor agonist and sodium-glucose Cotransporter-2 inhibitor therapies in patients with heart failure and diabetes. JAMA Netw Open 6(6):e2316290","journal-title":"JAMA Netw Open"},{"issue":"25","key":"827_CR14","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1016\/j.jacc.2022.04.031","volume":"79","author":"KF Faridi","year":"2022","unstructured":"Faridi KF, Dayoub EJ, Ross JS, Dhruva SS, Ahmad T, Desai NR (2022) Medicare coverage and out-of-pocket costs of quadruple drug therapy for heart failure. J Am Coll Cardiol 79(25):2516\u20132525","journal-title":"J Am Coll Cardiol"},{"key":"827_CR15","volume-title":"Guidance for industry diabetes mellitus\u2014evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes","author":"FDA","year":"2008","unstructured":"FDA (2008) Guidance for industry diabetes mellitus\u2014evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. FDA"},{"issue":"19","key":"827_CR16","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","volume":"37","author":"D Fitchett","year":"2016","unstructured":"Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A et al (2016) Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial. Eur Heart J 37(19):1526\u20131534","journal-title":"Eur Heart J"},{"issue":"2","key":"827_CR17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"E-KC Group","year":"2023","unstructured":"Group E-KC (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388(2):117\u2013127","journal-title":"N Engl J Med"},{"issue":"15","key":"827_CR18","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"JL Heerspink Hiddo","year":"2020","unstructured":"Heerspink Hiddo JL, Stef\u00e1nsson Bergur V, Correa-Rotter R, Chertow Glenn M, Greene T, Hou F-F et al (2020) Dapagliflozin in patients with chronic Kidney disease. N Engl J Med 383(15):1436\u20131446","journal-title":"N Engl J Med"},{"issue":"17","key":"827_CR19","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 79(17):e263\u2013e421","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"827_CR20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234065","volume":"15","author":"J Heyward","year":"2020","unstructured":"Heyward J, Mansour O, Olson L, Singh S, Alexander GC (2020) Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis. PLoS One 15(6):e0234065","journal-title":"PLoS One"},{"issue":"2","key":"827_CR21","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M et al (2018) How does Empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 41(2):356\u2013363","journal-title":"Diabetes Care"},{"issue":"3","key":"827_CR22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/flgastro-2024-102856","volume":"16","author":"SD Isaacs","year":"2025","unstructured":"Isaacs SD, Farrelly FV, Brennan PN (2025) Role of anti-diabetic medications in the management of MASLD. Frontline Gastroenterol 16(3):239\u2013249","journal-title":"Frontline Gastroenterol"},{"issue":"3","key":"827_CR23","first-page":"101615","volume":"4","author":"V Jaiswal","year":"2025","unstructured":"Jaiswal V, Ang SP, Kumar D, Deb N, Jaiswal A, Joshi A et al (2025) Sodium-glucose cotransporter-2 inhibitors and arrhythmias: a meta-analysis of 38 randomized controlled trials. JACC: Adv 4(3):101615","journal-title":"JACC: Adv"},{"issue":"2","key":"827_CR24","doi-asserted-by":"crossref","first-page":"EVIDoa2300286","DOI":"10.1056\/EVIDoa2300286","volume":"3","author":"S James","year":"2024","unstructured":"James S, Erlinge D, Storey RF, McGuire DK, de Belder M, Eriksson N et al (2024) Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evidence 3(2):EVIDoa2300286","journal-title":"NEJM Evidence"},{"key":"827_CR25","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108737","volume":"174","author":"T Karagiannis","year":"2021","unstructured":"Karagiannis T, Tsapas A, Athanasiadou E, Avgerinos I, Liakos A, Matthews DR et al (2021) GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 174:108737","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"827_CR26","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","volume":"143","author":"MM Lee","year":"2021","unstructured":"Lee MM, Brooksbank KJ, Wetherall K, Mangion K, Roditi G, Campbell RT et al (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation 143(6):516\u2013525","journal-title":"Circulation"},{"issue":"7","key":"827_CR27","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1210\/clinem\/dgab274","volume":"106","author":"DS-H Lin","year":"2021","unstructured":"Lin DS-H, Lee J-K, Chen W-J (2021) Clinical adverse events associated with sodium\u2013glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals. J Clin Endocrinol Metabol 106(7):2133\u20132145","journal-title":"J Clin Endocrinol Metabol"},{"key":"827_CR28","doi-asserted-by":"crossref","first-page":"e083735","DOI":"10.1136\/bmj-2024-083735","volume":"389","author":"J Lin","year":"2025","unstructured":"Lin J, Huang Y, Xu B, Gu X, Huang J, Sun J et al (2025) Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ 389:e083735","journal-title":"BMJ"},{"issue":"6","key":"827_CR29","volume":"6","author":"J Luo","year":"2023","unstructured":"Luo J, Feldman R, Callaway Kim K, Rothenberger S, Korytkowski M, Hernandez I et al (2023) Evaluation of out-of-pocket costs and treatment intensification with an SGLT2 inhibitor or GLP-1 RA in patients with type 2 diabetes and cardiovascular disease. JAMA Netw Open 6(6):e2317886","journal-title":"JAMA Netw Open"},{"issue":"1","key":"827_CR30","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.clinthera.2023.10.014","volume":"46","author":"R Maxson","year":"2024","unstructured":"Maxson R, Starr J, Sewell J, Lyas C (2024) SGLT2 inhibitors to slow chronic Kidney disease progression: a review. Clin Ther 46(1):e23\u2013ee8","journal-title":"Clin Ther"},{"issue":"37","key":"827_CR31","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M et al (2023) 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 44(37):3627\u20133639","journal-title":"Eur Heart J"},{"issue":"21","key":"827_CR32","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJ McMurray","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008","journal-title":"N Engl J Med"},{"issue":"2","key":"827_CR33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.102583","volume":"5","author":"A Mukhopadhyay","year":"2026","unstructured":"Mukhopadhyay A, Adhikari S, Li X, Kazi DS, Berman AN, Kronish I et al (2026) Prior authorization requirements and prescription fill patterns among patients with heart failure. JACC Adv 5(2):102583","journal-title":"JACC Adv"},{"issue":"18","key":"827_CR34","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","volume":"140","author":"ME Nassif","year":"2019","unstructured":"Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE et al (2019) Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation 140(18):1463\u20131476","journal-title":"Circulation"},{"issue":"20","key":"827_CR35","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS et al (2023) Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation 148(20):1606\u20131635","journal-title":"Circulation"},{"issue":"7","key":"827_CR36","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, De Zeeuw D, Fulcher G, Erondu N et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657","journal-title":"N Engl J Med"},{"issue":"15","key":"827_CR37","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424","journal-title":"N Engl J Med"},{"issue":"16","key":"827_CR38","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","volume":"144","author":"M Packer","year":"2021","unstructured":"Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ et al (2021) Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial. Circulation 144(16):1284\u20131294","journal-title":"Circulation"},{"issue":"20","key":"827_CR39","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.jacc.2024.07.013","volume":"84","author":"M Packer","year":"2024","unstructured":"Packer M, Ferreira JP, Butler J, Filippatos G, Januzzi JL, Gonz\u00e1lez Maldonado S et al (2024) Reaffirmation of mechanistic proteomic signatures accompanying SGLT2 inhibition in patients with heart failure: a validation cohort of the EMPEROR program. J Am Coll Cardiol 84(20):1979\u20131994","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"827_CR40","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","volume":"149","author":"SM Patel","year":"2024","unstructured":"Patel SM, Kang YM, Im K, Neuen BL, Anker SD, Bhatt DL et al (2024) Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis. Circulation 149(23):1789\u20131801","journal-title":"Circulation"},{"issue":"24","key":"827_CR41","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJ, Charytan DM et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295\u20132306","journal-title":"N Engl J Med"},{"issue":"14","key":"827_CR42","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","volume":"323","author":"MC Petrie","year":"2020","unstructured":"Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, B\u011blohl\u00e1vek J et al (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA 323(14):1353\u20131368","journal-title":"JAMA"},{"issue":"15","key":"827_CR43","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383\u20131392","journal-title":"N Engl J Med"},{"issue":"3","key":"827_CR44","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","volume":"77","author":"CG Santos-Gallego","year":"2021","unstructured":"Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S et al (2021) Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 77(3):243\u2013255","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"827_CR45","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jacc.2024.05.057","volume":"84","author":"J-I Shin","year":"2024","unstructured":"Shin J-I, Xu Y, Chang AR, Carrero JJ, Flaherty CM, Mukhopadhyay A et al (2024) Prescription patterns for sodium-glucose cotransporter 2 inhibitors in U.S. health systems. JACC 84(8):683\u2013693","journal-title":"JACC"},{"issue":"5","key":"827_CR46","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","volume":"37","author":"SD Solomon","year":"2016","unstructured":"Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK et al (2016) Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37(5):455\u2013462","journal-title":"Eur Heart J"},{"issue":"17","key":"827_CR47","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJ, Anand IS, Ge J, Lam CS, Maggioni AP et al (2019) Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381(17):1609\u20131620","journal-title":"N Engl J Med"},{"issue":"12","key":"827_CR48","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJ, Claggett B, de Boer RA, DeMets D, Hernandez AF et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387(12):1089\u20131098","journal-title":"N Engl J Med"},{"issue":"20","key":"827_CR49","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","volume":"76","author":"JA Spertus","year":"2020","unstructured":"Spertus JA, Jones PG, Sandhu AT, Arnold SV (2020) Interpreting the Kansas City cardiomyopathy questionnaire in clinical trials and clinical care: JACC state-of-the-art review. J Am Coll Cardiol 76(20):2379\u20132390","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"827_CR50","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK et al (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105(4):S117\u2013S314","journal-title":"Kidney Int"},{"issue":"3","key":"827_CR51","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"F Tacke","year":"2024","unstructured":"Tacke F, Horn P, Wong VW-S, Ratziu V, Bugianesi E, Francque S et al (2024) EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 81(3):492\u2013542","journal-title":"J Hepatol"},{"issue":"21","key":"827_CR52","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1161\/CIRCULATIONAHA.122.059032","volume":"146","author":"M Tonelli","year":"2022","unstructured":"Tonelli M, Straus S (2022) Increasing societal benefit from cardiovascular drugs. Circulation 146(21):1627\u20131635","journal-title":"Circulation"},{"issue":"12","key":"827_CR53","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.4205","volume":"2","author":"SL Tummalapalli","year":"2021","unstructured":"Tummalapalli SL, Montealegre JL, Warnock N, Green M, Ibrahim SA, Estrella MM (2021) Coverage, formulary restrictions, and affordability of sodium-glucose cotransporter 2 inhibitors by US insurance plan types. JAMA Health Forum 2(12):e214205","journal-title":"JAMA Health Forum"},{"issue":"6","key":"827_CR54","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1161\/CIRCULATIONAHA.122.060823","volume":"146","author":"K Umanath","year":"2022","unstructured":"Umanath K, Testani JM, Lewis JB (2022) \u201cDip\u201d in eGFR: stay the course with SGLT-2 inhibition. Circulation 146(6):463\u2013465","journal-title":"Circulation"},{"issue":"5","key":"827_CR55","doi-asserted-by":"crossref","first-page":"771","DOI":"10.34067\/KID.0000000000000425","volume":"5","author":"A Upadhyay","year":"2024","unstructured":"Upadhyay A (2024) SGLT2 inhibitors and Kidney protection: mechanisms beyond Tubuloglomerular feedback. Kidney 360 5(5):771\u2013782","journal-title":"Kidney 360"},{"issue":"7","key":"827_CR56","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","volume":"12","author":"MS Usman","year":"2024","unstructured":"Usman MS, Bhatt DL, Hameed I, Anker SD, Cheng AY, Hernandez AF et al (2024) Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 12(7):447\u2013461","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"827_CR57","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1001\/jamacardio.2022.3750","volume":"7","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Claggett BL, Jhund P, de Boer RA, Hernandez AF, Inzucchi SE et al (2022) Time to clinical benefit of Dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction: a Prespecified secondary analysis of the DELIVER randomized clinical trial. JAMA Cardiol 7(12):1259\u20131263","journal-title":"JAMA Cardiol"},{"issue":"11","key":"827_CR58","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/ajh\/hpae092","volume":"37","author":"V Vallon","year":"2024","unstructured":"Vallon V (2024) State-of-the-art-review: mechanisms of action of SGLT2 inhibitors and clinical implications. Am J Hypertens 37(11):841\u2013852","journal-title":"Am J Hypertens"},{"issue":"2","key":"827_CR59","doi-asserted-by":"crossref","first-page":"glad181","DOI":"10.1093\/gerona\/glad181","volume":"79","author":"P Vart","year":"2024","unstructured":"Vart P, Butt JH, Jongs N, Schechter M, Chertow GM, Wheeler DC et al (2024) Efficacy and safety of dapagliflozin in patients with chronic kidney disease across the spectrum of frailty. J Gerontol: Ser A 79(2):glad181","journal-title":"J Gerontol: Ser A"},{"issue":"10","key":"827_CR60","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJ (2018) SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia 61(10):2108\u20132117","journal-title":"Diabetologia"},{"issue":"21","key":"827_CR61","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H et al (2019) Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation 140(21):1693\u20131702","journal-title":"Circulation"},{"issue":"1","key":"827_CR62","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12325-023-02652-5","volume":"41","author":"S Verma","year":"2024","unstructured":"Verma S, Mudaliar S, Greasley PJ (2024) Potential underlying mechanisms explaining the cardiorenal benefits of sodium\u2013glucose cotransporter 2 inhibitors. Adv Ther 41(1):92\u2013112","journal-title":"Adv Ther"},{"issue":"3","key":"827_CR63","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J et al (2022) The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 28(3):568\u2013574","journal-title":"Nat Med"},{"issue":"4","key":"827_CR64","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323\u2013334","journal-title":"N Engl J Med"},{"issue":"4","key":"827_CR65","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u2013357","journal-title":"N Engl J Med"},{"issue":"48","key":"827_CR66","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1093\/eurheartj\/ehac495","volume":"43","author":"F Zannad","year":"2022","unstructured":"Zannad F, Ferreira JP, Butler J, Filippatos G, Januzzi JL, Sumin M et al (2022) Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme. Eur Heart J 43(48):4991\u20135002","journal-title":"Eur Heart J"},{"issue":"10166","key":"827_CR67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166):31\u201339","journal-title":"Lancet"},{"issue":"22","key":"827_CR68","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128","journal-title":"N Engl J Med"}],"container-title":["Handbook of Experimental Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2026_827","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:29:08Z","timestamp":1789194548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2026_827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":68,"URL":"https:\/\/doi.org\/10.1007\/164_2026_827","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"13 September 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}